Intravenous immunoglobulin (IVIG), a pooled normal IgG from several thousand healthy donors and one of the commonly used immunotherapeutic molecules for the management of autoimmune and inflammatory diseases, has been explored for the treatment of coronavirus disease-19 (COVID-19). Although placebo-controlled, double-blind randomised clinical trials are lacking, current data from either retrospective, case series or open-label randomised controlled trials provide an indicator that IVIG immunotherapy could benefit severe and critically ill COVID-19 patients. See alsoShao et al.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565103 | PMC |
| http://dx.doi.org/10.1002/cti2.1198 | DOI Listing |
Publication Analysis
Top Keywords
intravenous immunoglobulin
8
coronavirus disease-19
8
disease-19 covid-19
8
immunoglobulin immunotherapy
4
immunotherapy coronavirus
4
covid-19 intravenous
4
immunoglobulin ivig
4
ivig pooled
4
pooled normal
4
normal igg
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!